SLC45A3

Solute carrier family 45, member 3
Identifiers
Symbols	SLC45A3 ; IPCA-2; IPCA-6; IPCA-8; IPCA6; PCANAP2; PCANAP6; PCANAP8; PRST
External IDs	OMIM: 605097 MGI: 1922082 HomoloGene: 23813 IUPHAR: 1211 GeneCards: SLC45A3 Gene
Gene ontology Molecular function • sodium:dicarboxylate symporter activity Cellular component • integral component of membrane Biological process • transmembrane transport Sources: Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	85414	212980
Ensembl	ENSG00000158715	ENSMUSG00000026435
UniProt	Q96JT2	Q8K0H7
RefSeq (mRNA)	NM_033102	NM_001177628
RefSeq (protein)	NP_149093	NP_001171099
Location (UCSC)	Chr 1: 205.66 – 205.68 Mb	Chr 1: 131.96 – 131.98 Mb
PubMed search

Solute carrier family 45 member 3 (SLC45A3), also known as prostate cancer-associated protein 6 or prostein, is a protein that in humans is encoded by the SLC45A3 gene.^[1][2][3]

SLC45A3 is expressed in a prostate-specific manner by normal tissues and at a significantly lower level in prostate tumor cell lines. Treatment prostate cancer cell lines with androgens upregulates the expression of SLC45A3.^[3]

Regulation

There is evidence that the expression of SLC45A3 is regulated by the microRNA mir-126*.^[4]

References

1. "Entrez Gene: solute carrier family 45".
2. Walker MG, Volkmuth W, Sprinzak E, Hodgson D, Klingler T (December 1999). "Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes". Genome Res. 9 (12): 1198–203. doi:10.1101/gr.9.12.1198. PMC 310991. PMID 10613842.
3. Xu J, Kalos M, Stolk JA, Zasloff EJ, Zhang X, Houghton RL, Filho AM, Nolasco M, Badaró R, Reed SG (February 2001). "Identification and characterization of prostein, a novel prostate-specific protein". Cancer Res. 61 (4): 1563–8. PMID 11245466.
4. Musiyenko A, Bitko V, Barik S (2008). "Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells.". J Mol Med 86 (3): 313–22. doi:10.1007/s00109-007-0296-9. PMC 3263384. PMID 18193184.

Further reading

• Pflueger D, Rickman DS, Sboner A, et al. (2009). "N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.". Neoplasia 11 (8): 804–11. PMC 2713587. PMID 19649210.
• Helgeson BE, Tomlins SA, Shah N, et al. (2008). "Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.". Cancer Res. 68 (1): 73–80. doi:10.1158/0008-5472.CAN-07-5352. PMID 18172298.
• Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
• Esgueva R, Perner S, J LaFargue C, et al. (2010). "Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.". Mod. Pathol. 23 (4): 539–46. doi:10.1038/modpathol.2009.193. PMC 2848699. PMID 20118910.
• Strausberg RL, Feingold EA, Grouse LH, et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
• Kimura K, Wakamatsu A, Suzuki Y, et al. (2006). "Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.". Genome Res. 16 (1): 55–65. doi:10.1101/gr.4039406. PMC 1356129. PMID 16344560.
• Friedman RS, Spies AG, Kalos M (2004). "Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate.". Eur. J. Immunol. 34 (4): 1091–101. doi:10.1002/eji.200324768. PMID 15048720.
• Maher CA, Kumar-Sinha C, Cao X, et al. (2009). "Transcriptome sequencing to detect gene fusions in cancer.". Nature 458 (7234): 97–101. doi:10.1038/nature07638. PMC 2725402. PMID 19136943.
• Musiyenko A, Bitko V, Barik S (2008). "Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells.". J. Mol. Med. 86 (3): 313–22. doi:10.1007/s00109-007-0296-9. PMC 3263384. PMID 18193184.
• Kiessling A, Stevanovic S, Füssel S, Weigle B, Rieger MA, Temme A, Rieber EP, Schmitz M (March 2004). "Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein". Br. J. Cancer 90 (5): 1034–40. doi:10.1038/sj.bjc.6601642. PMC 2410218. PMID 14997204.
• Satake W, Nakabayashi Y, Mizuta I, et al. (2009). "Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease.". Nat. Genet. 41 (12): 1303–7. doi:10.1038/ng.485. PMID 19915576.
• Kalos M, Askaa J, Hylander BL, et al. (2004). "Prostein expression is highly restricted to normal and malignant prostate tissues.". Prostate 60 (3): 246–56. doi:10.1002/pros.20043. PMID 15176054.
• Sheridan T, Herawi M, Epstein JI, Illei PB (2007). "The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.". Am. J. Surg. Pathol. 31 (9): 1351–5. doi:10.1097/PAS.0b013e3180536678. PMID 17721190.